AcelRx Pharmaceuticals, Inc.

Free In-Depth Equity Research Report

On September 22, 2015, AcelRx announced that the European Commission (EC) approved Zalviso™ (sufentanil sublingual tablet system) for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting. Going forward ... (see research report)

Access Your AcelRx Pharmaceuticals, Inc. Report Now!